Lizhu Medicine: NS-041 tablets received clinical trial approval for the addition of the indication "treatment of depression"

Lizhu Pharmaceuticals announced that its wholly-owned subsidiary Lizhu Pharmaceutical Factory has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for NS-041 tablets, approving the conduct of clinical trials for the indication of "treating depression." NS-041 tablets is a novel highly selective KCNQ2/3 agonist, which was approved in 2023 to conduct clinical trials for the indication of epilepsy, and is currently in Phase II clinical research. The drug is scheduled to be introduced by Lizhu Pharmaceutical Factory in 2024, with a total research and development investment of approximately 58.5394 million yuan as of the disclosure date of the announcement. There is currently no new generation targeted KCNQ2/3 drug on the market in China. Drug development involves uncertainties, and the company will disclose progress in a timely manner.